期刊
IMMUNOTHERAPY
卷 9, 期 2, 页码 183-196出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2016-0112
关键词
adoptive cell therapy; cancer immunotherapy; tumor-infiltrating lymphocytes
类别
资金
- Israel Science Foundation [2303/16]
- Adelson Medical Research Foundation
The immune system is a potent inhibitor of tumor growth with curative potential, constituting in many eyes the future of antineoplastic therapy. Adoptive cell therapy (ACT) is a form of immunotherapy in which autologous cancer-cognate lymphocytes are expanded and modified ex vivo and re-infused to combat the tumor. This review follows the evolvement of ACT and treatment protocols, focusing on unresolved dilemmas regarding this treatment while providing evidence for its effectiveness in refractory patients. Future directions of ACT are discussed, in particular with regard to genetic engineering of autologous cells, and the role of ACT in the era of checkpoint inhibitors is addressed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据